Peptide News Digest

#Written-Comments

2 stories

Regulatory · View digest

PCAC Written-Comment Docket FDA-2025-N-6895 Reaches Member-Review Deadline at 11:59 PM ET on Thursday July 9; Comments Filed by This Cutoff Go Into the Reading Packet Panelists Use to Prepare, Comments After Today Remain on the Record but Reach Members After Initial Review; Absolute Hard Deadline for All Written Submissions Remains 11:59 PM ET on Wednesday July 22 Ahead of the July 23-24 Meeting on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon

The FDA Pharmacy Compounding Advisory Committee written-comment docket FDA-2025-N-6895 reaches its member-review cutoff Thursday July 9, 2026 at 11:59 PM ET. Submissions filed by this deadline go into the reading packet PCAC members review ahead of the July 23-24 meeting. Written comments filed after today remain on the public record and inform final agency deliberations but do not reach panelists before their initial preparation. The absolute hard deadline for all written comment submissions is 11:59 PM ET on Wednesday July 22, 2026, one day before the meeting opens at White Oak. The docket has attracted comments from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices), academic scientists (UC Davis's Paul Knoepfler), and individual physicians and patients on both sides. The FDA career-staff briefing documents released June 29-30 concluded all seven peptides have insufficient evidence for 503A bulks list eligibility, citing immunogenicity, heavy-metal and microbial contamination in compounded samples, mislabeled contents, and thin 503A historical use. The July 9 threshold locks in the reading pile that panelists carry into the July 23 vote.

Regulatory · View digest

PCAC Written-Comment Docket FDA-2025-N-6895 Closes Thursday July 9 at 11:59 PM ET for Advisory-Committee Member Review Ahead of the July 23-24 Meeting on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon; Hard Deadline for All Written Submissions Remains July 22

The FDA Pharmacy Compounding Advisory Committee written-comment docket FDA-2025-N-6895 reaches its first procedural cutoff Thursday July 9, 2026 at 11:59 PM ET. Comments submitted by this deadline will be formally provided to PCAC members ahead of the July 23-24 meeting. Written submissions after July 9 remain on the record but reach members after their initial review preparation. The docket's absolute hard deadline for all written comment submissions is July 22, 2026 at 11:59 PM ET (one day before the meeting opens). Compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer advocacy voices (Public Citizen), academic researchers (UC Davis's Paul Knoepfler), and individual physicians have filed comments across both the pro-approval and pro-restriction sides of the panel decision. The FDA career-staff briefing documents (released June 29-30) concluded all seven peptides have insufficient evidence for 503A bulks list eligibility, citing immunogenicity concerns, heavy-metal and microbial contamination in compounded product samples, mislabeled contents, and thin 503A historical use. The July 9 threshold is the operational moment at which panelists get their reading pile; the record they use to deliberate the July 23-24 vote is set today.